Yasutaka Kakinoki

Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M‐sol)

Hiroshi Azuma, Junichi Hirayama, Mitsuaki Akino et al. · Transfusion · 2008 · 103 citations

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 100 citations

Hematological Malignancy, Medicine, First-line Dadi Trial +9

Risk factor analysis of non‐Hodgkin lymphoma‐associated haemophagocytic syndromes: a multicentre study

Hirozumi Sano, Ryōji Kobayashi, Junji Tanaka et al. · British Journal of Haematology · 2014 · 53 citations

Multisite Phosphorylation and the Nuclear Localization of Phosphatase Inhibitor 2-Green Fluorescent Protein Fusion Protein during S Phase of the Cell Growth Cycle

Yasutaka Kakinoki, Jeremy P. Somers, David L. Brautigan · Journal of Biological Chemistry · 1997 · 42 citations · Full text

Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT

Ryōji Kobayashi, Junji Tanaka, Satoshi Hashino et al. · Bone Marrow Transplantation · 2013 · 35 citations

Inflammation, Etoposide-containing Conditioning Regimen, Apoptosis +10